The estimated Net Worth of Capital Granite, L.P.Saints... is at least $23.3 Milhão dollars as of 11 October 2013. Capital Saints owns over 32,301 units of Enanta Pharmaceuticals Inc stock worth over $17,165,524 and over the last 12 years Capital sold ENTA stock worth over $6,128,906.
Capital has made over 4 trades of the Enanta Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital sold 32,301 units of ENTA stock worth $640,852 on 11 October 2013.
The largest trade Capital's ever made was selling 200,000 units of Enanta Pharmaceuticals Inc stock on 30 September 2013 worth over $4,702,000. On average, Capital trades about 83,746 units every 50 days since 2013. As of 11 October 2013 Capital still owns at least 1,425,708 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Capital Saints stock trades at the bottom of the page.
Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., eYat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: